Merck & Co.
AWARDS
NEWS
In its 2Q2021 Clinical Report, BioSpace highlights drugs that were greenlit for clinical studies, faced clinical and regulatory hurdles and some who saw regulatory wins.
The expanded approval was made based on positive data from a second interim analysis of the Phase II KEYNOTE-629 trial.
NGM Biopharmaceuticals and Merck announced they had amended their existing collaboration agreement. It will continue through March 2024, but have a narrower scope.
Alpine Immune Sciences has entered into a collaboration agreement with Merck to evaluate the efficacy and safety of Alpine’s checkpoint in combination with Merk’s anti-PD-1 therapy in cancer.
Here’s a look at some of the top COVID-19-related stories for today.
If approved, lenacapavir would be offered to HIV patients who have been heavily treated for the disease and have multi-drug-resistant HIV.
JOBS
IN THE PRESS